Genfit SA
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more
Genfit SA (GNFTF) - Net Assets
Latest net assets as of June 2025: $52.47 Million USD
Based on the latest financial reports, Genfit SA (GNFTF) has net assets worth $52.47 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($216.68 Million) and total liabilities ($164.21 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $52.47 Million |
| % of Total Assets | 24.22% |
| Annual Growth Rate | 8.32% |
| 5-Year Change | N/A |
| 10-Year Change | 24.92% |
| Growth Volatility | 126.73 |
Genfit SA - Net Assets Trend (2004–2024)
This chart illustrates how Genfit SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genfit SA (2004–2024)
The table below shows the annual net assets of Genfit SA from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $69.22 Million | +1.87% |
| 2023-12-31 | $67.95 Million | -28.12% |
| 2022-12-31 | $94.53 Million | -20.63% |
| 2021-12-31 | $119.10 Million | +836.90% |
| 2020-12-31 | $-16.16 Million | -119.23% |
| 2019-12-31 | $84.06 Million | +301.48% |
| 2018-12-31 | $20.94 Million | -79.91% |
| 2017-12-31 | $104.23 Million | -27.01% |
| 2016-12-31 | $142.80 Million | +157.68% |
| 2015-12-31 | $55.42 Million | -21.32% |
| 2014-12-31 | $70.43 Million | +399.74% |
| 2013-12-31 | $14.09 Million | +106.22% |
| 2012-12-31 | $6.83 Million | +53.33% |
| 2011-12-31 | $4.46 Million | -46.87% |
| 2010-12-31 | $8.39 Million | -45.95% |
| 2009-12-31 | $15.52 Million | -30.66% |
| 2008-12-31 | $22.38 Million | -11.77% |
| 2007-12-31 | $25.37 Million | -8.65% |
| 2006-12-31 | $27.77 Million | +107.45% |
| 2005-12-31 | $13.39 Million | -4.37% |
| 2004-12-31 | $14.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genfit SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18258.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.50 Million | 18.06% |
| Other Comprehensive Income | $347.00K | 0.50% |
| Other Components | $446.95 Million | 645.65% |
| Total Equity | $69.22 Million | 100.00% |
Genfit SA Competitors by Market Cap
The table below lists competitors of Genfit SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
United States Cellular Corporation
NYSE:USM
|
$144.59 Million |
|
Sylvania Platinum Limited
OTCGREY:SAPLF
|
$144.66 Million |
|
Zhejiang Changhua Auto Parts Co Ltd
SHG:605018
|
$144.68 Million |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
$144.69 Million |
|
Jmicron Technology
TWO:4925
|
$144.51 Million |
|
Asia Cuanon Tech (Shanghai)
SHG:603378
|
$144.49 Million |
|
Fundamental Global Inc.
NASDAQ:FGNXP
|
$144.39 Million |
|
DR Corporation Limited
SHE:301177
|
$144.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genfit SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 67,951,000 to 69,224,000, a change of 1,273,000 (1.9%).
- Net income of 1,507,000 contributed positively to equity growth.
- New share issuances of 61,000 increased equity.
- Other comprehensive income decreased equity by 649,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.51 Million | +2.18% |
| Share Issuances | $61.00K | +0.09% |
| Other Comprehensive Income | $-649.00K | -0.94% |
| Other Changes | $354.00K | +0.51% |
| Total Change | $- | 1.87% |
Book Value vs Market Value Analysis
This analysis compares Genfit SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.57x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.07x to 2.57x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $1.15 | $3.54 | x |
| 2005-12-31 | $1.15 | $3.54 | x |
| 2006-12-31 | $2.39 | $3.54 | x |
| 2007-12-31 | $2.18 | $3.54 | x |
| 2008-12-31 | $1.93 | $3.54 | x |
| 2009-12-31 | $1.34 | $3.54 | x |
| 2010-12-31 | $0.70 | $3.54 | x |
| 2011-12-31 | $0.35 | $3.54 | x |
| 2012-12-31 | $0.45 | $3.54 | x |
| 2013-12-31 | $0.70 | $3.54 | x |
| 2014-12-31 | $3.07 | $3.54 | x |
| 2015-12-31 | $2.24 | $3.54 | x |
| 2016-12-31 | $5.32 | $3.54 | x |
| 2017-12-31 | $3.34 | $3.54 | x |
| 2018-12-31 | $0.67 | $3.54 | x |
| 2019-12-31 | $2.27 | $3.54 | x |
| 2020-12-31 | $-0.42 | $3.54 | x |
| 2021-12-31 | $2.14 | $3.54 | x |
| 2022-12-31 | $1.90 | $3.54 | x |
| 2023-12-31 | $1.37 | $3.54 | x |
| 2024-12-31 | $1.38 | $3.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genfit SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.25%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 2.19x
- Recent ROE (2.18%) is above the historical average (-54.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 18.65% | 17.33% | 0.41x | 2.65x | $997.54K |
| 2005 | 13.29% | 13.88% | 0.41x | 2.31x | $438.76K |
| 2006 | 1.18% | 3.26% | 0.22x | 1.67x | $-2.45 Million |
| 2007 | -11.04% | -29.55% | 0.24x | 1.59x | $-5.34 Million |
| 2008 | -17.70% | -45.21% | 0.19x | 2.05x | $-6.20 Million |
| 2009 | -47.51% | -126.87% | 0.15x | 2.48x | $-8.93 Million |
| 2010 | -111.82% | -249.65% | 0.12x | 3.74x | $-10.22 Million |
| 2011 | -217.22% | -410.09% | 0.08x | 6.52x | $-10.13 Million |
| 2012 | -79.19% | -323.60% | 0.07x | 3.45x | $-6.09 Million |
| 2013 | -89.78% | -666.15% | 0.07x | 2.07x | $-14.06 Million |
| 2014 | -24.17% | -1054.60% | 0.02x | 1.23x | $-24.07 Million |
| 2015 | -30.92% | -3251.42% | 0.01x | 1.25x | $-22.68 Million |
| 2016 | -23.58% | -11854.58% | 0.00x | 1.16x | $-47.95 Million |
| 2017 | -56.23% | -49664.41% | 0.00x | 2.81x | $-69.03 Million |
| 2018 | -379.77% | -115247.83% | 0.00x | 10.96x | $-81.61 Million |
| 2019 | -77.49% | -211.24% | 0.10x | 3.69x | $-73.55 Million |
| 2020 | 0.00% | -13231.50% | 0.00x | 0.00x | $-99.60 Million |
| 2021 | 56.47% | 84.00% | 0.28x | 2.37x | $55.35 Million |
| 2022 | -25.09% | -117.45% | 0.09x | 2.28x | $-33.17 Million |
| 2023 | -42.52% | -101.15% | 0.16x | 2.56x | $-35.69 Million |
| 2024 | 2.18% | 2.25% | 0.44x | 2.19x | $-5.42 Million |
Industry Comparison
This section compares Genfit SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genfit SA (GNFTF) | $52.47 Million | 18.65% | 3.13x | $144.56 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |